Literature DB >> 22583459

Mapping from disease-specific measures to health-state utility values in individuals with migraine.

Patrick J Gillard1, Beth Devine, Sepideh F Varon, Lei Liu, Sean D Sullivan.   

Abstract

OBJECTIVE: The objective of this study was to develop empirical algorithms that estimate health-state utility values from disease-specific quality-of-life scores in individuals with migraine.
METHODS: Data from a cross-sectional, multicountry study were used. Individuals with episodic and chronic migraine were randomly assigned to training or validation samples. Spearman's correlation coefficients between paired EuroQol five-dimensional (EQ-5D) questionnaire utility values and both Headache Impact Test (HIT-6) scores and Migraine-Specific Quality-of-Life Questionnaire version 2.1 (MSQ) domain scores (role restrictive, role preventive, and emotional function) were examined. Regression models were constructed to estimate EQ-5D questionnaire utility values from the HIT-6 score or the MSQ domain scores. Preferred algorithms were confirmed in the validation samples.
RESULTS: In episodic migraine, the preferred HIT-6 and MSQ algorithms explained 22% and 25% of the variance (R(2)) in the training samples, respectively, and had similar prediction errors (root mean square errors of 0.30). In chronic migraine, the preferred HIT-6 and MSQ algorithms explained 36% and 45% of the variance in the training samples, respectively, and had similar prediction errors (root mean square errors 0.31 and 0.29). In episodic and chronic migraine, no statistically significant differences were observed between the mean observed and the mean estimated EQ-5D questionnaire utility values for the preferred HIT-6 and MSQ algorithms in the validation samples.
CONCLUSIONS: The relationship between the EQ-5D questionnaire and the HIT-6 or the MSQ is adequate to use regression equations to estimate EQ-5D questionnaire utility values. The preferred HIT-6 and MSQ algorithms will be useful in estimating health-state utilities in migraine trials in which no preference-based measure is present.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22583459     DOI: 10.1016/j.jval.2011.12.007

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

1.  The cost effectiveness of Botox in Italian patients with chronic migraine.

Authors:  M Ruggeri
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

2.  Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.

Authors:  Ronan Mahon; Andrea Lang; Pamela Vo; Jasper Huels; Philip Cooney; Andriy Danyliv; Umakanth Vudumula; Sreelatha Vadapalle; Farooq Maniyar; Peter J Goadsby
Journal:  Pharmacoeconomics       Date:  2021-01-25       Impact factor: 4.981

Review 3.  Burden of allergic respiratory disease: a systematic review.

Authors:  A Linneberg; K Dam Petersen; J Hahn-Pedersen; E Hammerby; N Serup-Hansen; N Boxall
Journal:  Clin Mol Allergy       Date:  2016-09-28

4.  Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).

Authors:  Kirstie L Haywood; Tom S Mars; Rachel Potter; Shilpa Patel; Manjit Matharu; Martin Underwood
Journal:  Cephalalgia       Date:  2017-09-18       Impact factor: 6.292

5.  Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.

Authors:  Karissa M Johnston; Gilbert L'Italien; Evan Popoff; Lauren Powell; Robert Croop; Alexandra Thiry; Linda Harris; Vladimir Coric; Richard B Lipton
Journal:  Adv Ther       Date:  2021-08-29       Impact factor: 3.845

6.  The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome.

Authors:  Rosel Sturkenboom; Daniel Keszthelyi; Lloyd Brandts; Zsa Zsa R M Weerts; Johanna T W Snijkers; Ad A M Masclee; Brigitte A B Essers
Journal:  Qual Life Res       Date:  2021-09-21       Impact factor: 4.147

7.  Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).

Authors:  Karissa Johnston; Linda Harris; Lauren Powell; Evan Popoff; Vladimir Coric; Gilbert L'Italien; Curtis P Schreiber
Journal:  J Headache Pain       Date:  2022-01-17       Impact factor: 7.277

8.  Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis.

Authors:  Sylwia Bujkiewicz; John R Thompson; Alex J Sutton; Nicola J Cooper; Mark J Harrison; Deborah P M Symmons; Keith R Abrams
Journal:  Value Health       Date:  2014 Jan-Feb       Impact factor: 5.725

9.  Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment.

Authors:  Ning Yan Gu; Marc F Botteman; Robert A Gerber; Xiang Ji; Roelien Postema; Yin Wan; Grzegorz Sianos; Iain Anthony; Joseph C Cappelleri; Piotr Szczypa; Ben van Hout
Journal:  Acta Orthop       Date:  2013-11-29       Impact factor: 3.717

10.  Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Authors:  Gian Luca Di Tanna; Joshua K Porter; Richard B Lipton; Anthony J Hatswell; Sandhya Sapra; Guillermo Villa
Journal:  Health Qual Life Outcomes       Date:  2019-11-12       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.